Metastatic melanoma response to combination therapy with BRAF and MEK inhibitors: a FDG PET/CT pilot study

被引：0
|
作者：
Burroni, L.
Fringuelli, F.
Biscontini, G.
Palucci, A.
机构：
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2019年 / 46卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0446
引用
收藏
页码：S586 / S587
页数：2
相关论文
共 50 条
  • [41] Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma
    Oberle, Marion
    Jamme, Philippe
    Mansard, Sandrine
    Machet, Laurent
    Hervieu, Alice
    Kramkimel, Nora
    Greliak, Anna
    Jarrousse, Anne Sophie
    Derangere, Valentin
    Dudoignon, David
    Descarpentries, Clotilde
    Mortier, Laurent
    JCO PRECISION ONCOLOGY, 2022, 6
  • [42] Identifying and intervening rare resistant subclones to BRAF/MEK inhibitors in metastatic melanoma
    Wang, Han
    Nakazawa, Michael
    Veiseh, Omid
    Kwong, Lawrence
    Zhang, David
    CANCER RESEARCH, 2024, 84 (06)
  • [43] Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients
    Sponghini, Andrea P.
    Platini, Francesca
    Marra, Elena
    Rondonotti, David
    Alabiso, Oscar
    Fierro, Maria T.
    Savoia, Paola
    Stratica, Florian
    Quaglino, Pietro
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [44] Safety of BRAF and MEK inhibitors for treatment of metastatic melanoma: disproportionality analysis in VigiBase®
    Rousset, M.
    Gouverneur, A.
    Pariente, A.
    Miremont-Salame, G.
    Molimard, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 78 - 78
  • [45] Safety of BRAF and MEK Inhibitors for Treatment of Metastatic Melanoma: Disproportionality Analysis in Vigibase
    Rousset, M.
    Gouverneur, A.
    Miremont, G.
    Molimard, M.
    DRUG SAFETY, 2018, 41 (11) : 1210 - 1210
  • [46] Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma
    Fauviaux, E.
    Promelle, V
    Boucenna, V
    Jany, B.
    Errera, M. H.
    Delbarre, M.
    Boucenna, W.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2022, 45 (06): : 612 - 618
  • [47] The Role of Therapy Sequencing with Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors on the Response and Survival of Patients with metastatic BRAFV600-positive malignant Melanoma - a retrospective Cohort Study
    Haist, M.
    Stege, H.
    Ebner, R.
    Loquai, C.
    Grabbe, S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 20 - 20
  • [48] Unprecedented response to combination BRAF and MEK inhibitors in adult anaplastic ganglioglioma
    Benjamin Beland
    Roger Y. Tsang
    Garnette Sutherland
    Journal of Neuro-Oncology, 2018, 137 : 667 - 669
  • [49] Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
    Carlino, Matteo S.
    Fung, Carina
    Shahheydari, Hamideh
    Todd, Jason R.
    Boyd, Suzanah C.
    Irvine, Mal
    Nagrial, Adnan M.
    Scolyer, Richard A.
    Kefford, Richard F.
    Long, Georgina V.
    Rizos, Helen
    CLINICAL CANCER RESEARCH, 2015, 21 (01) : 98 - 105
  • [50] Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
    Pires da Silva, Ines
    Zakria, Danny
    Ahmed, Tasnia
    Trojanello, Claudia
    Dimitriou, Florentia
    Allayous, Clara
    Gerard, Camille
    Zimmer, Lisa
    Lo, Serigne
    Michielin, Olivier
    Lebbe, Celeste
    Mangana, Johanna
    Ascierto, Paolo Antonio
    Johnson, Douglas B.
    Carlino, Matteo
    Menzies, Alexander
    Long, Georgina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
12345